Paper Details

  1. Home
  2. Paper Details

The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.

Author: FuchikamiChiaki, HondaYohei, KosugiKeiji, KuramotoKazuya, KuwanoKeiichi, NumakuraYuki

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pulmonary arterial hypertension (PAH) is a serious condition that affects the arteries in the lungs. Selexipag is a drug that is used to treat PAH by activating the prostacyclin receptor. This study investigated the effects of selexipag on the pathology of PAH in rats. The study found that selexipag improved right ventricular systolic pressure and reduced right ventricular hypertrophy in rats with PAH. The study also found that selexipag reduced the number of occlusive lesions in the lung arteries and reduced the medial wall thickness of the arteries. These findings suggest that selexipag may be a promising treatment for PAH.
Paper Details　
Original Abstract of the Article :
Pulmonary arterial hypertension (PAH) is a lethal disease characterized by a progressive increase in pulmonary artery pressure due to an increase in vessel tone and occlusion of vessels. The endogenous vasodilator prostacyclin and its analogs are used as therapeutic agents for PAH. However, their ph...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561119/

データ提供：米国国立医学図書館（NLM）

Selexipag: A Promising Treatment for Pulmonary Arterial Hypertension

This research takes us on a journey into the challenging world of [cardiology], specifically focusing on the treatment of [pulmonary arterial hypertension (PAH)]. This condition, like a desert sandstorm that constricts the airways, can severely impact lung function and quality of life. The researchers investigated the effectiveness of [selexipag], a [selective prostacyclin receptor agonist], in a rat model of PAH. This approach, akin to meticulously studying the effects of a desert plant on a specific ecosystem, allowed them to gain valuable insights into the potential of selexipag in managing PAH. Their findings suggest that selexipag might be a promising treatment option for PAH, offering a ray of hope for individuals grappling with this challenging condition.

Unlocking the Power of Selexipag

The study revealed that selexipag, a [selective prostacyclin receptor agonist], demonstrated significant improvements in reducing pulmonary artery pressure and right ventricular hypertrophy in rats with PAH. This finding, like a well-spring discovered in a barren desert, offers valuable insights into the potential of selexipag as a treatment option for PAH.

Living Well with Pulmonary Arterial Hypertension

This research provides a glimmer of hope for individuals living with PAH. The study suggests that selexipag might offer a promising treatment option for this challenging condition. It is crucial to consult with a qualified cardiologist to determine the best course of treatment, as the journey of PAH management is unique for each individual.

Dr.Camel's Conclusion

This research offers a ray of hope in the challenging world of pulmonary arterial hypertension. The authors meticulously investigated the effectiveness of selexipag in a rat model of PAH, revealing its potential to reduce pulmonary artery pressure and right ventricular hypertrophy. Like a skilled desert navigator discovering a new route, this research opens up new possibilities for managing PAH and improving the quality of life for those affected by this condition.
Date :
  1. Date Completed 2020-12-09
  2. Date Revised 2020-12-14
Further Info :

Pubmed ID

33057388

DOI: Digital Object Identifier

PMC7561119

Related Literature

Article Analysis
・Effects of selexipag injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.